GSK and biotechnology company Muna Therapeutics have entered a research alliance to identify and validate novel drug targets for the treatment of Alzheimer’s disease.   The companies will explore insights from Muna’s MiND-MAP platform, which applies spatial transcriptomics to brain samples from Alzheimer’s disease patients, cognitively resilient individuals, healthy controls, and centenarians with and without cognitive […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!